These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from April 20 through April 26, 2023. Source: VerityData (verityplatform.com)
Increases in Holdings
Dlocal $(DLO)$
General Atlantic lifted its interest in the Uruguay-based payments processor to 63,096,501 shares. General Atlantic bought a total of 1,796,151 Dlocal shares at per share prices ranging from $13.65 to $16.86 from March 24 through April 25. All of the purchases occurred through a 10b5-1 plan adopted on Dec. 22, 2022, and lifted General Atlantic's stake to 38.9% of Dlocal's tradable stock. Dlocal's initial public offering was in June 2021. The payments company collected $617.6 million through the IPO after selling 29,411,765 shares priced at $21 each, which was above the $16 to $18 range it had told investors to expect.
Augmedix (AUGX)
Redmile Group boosted its position in the digital healthcare-services company to 20,246,320 shares, including 4,615,993 shares underlying exercisable warrants. On April 19, Redmile and Augmedix entered into a private-placement agreement through which Redmile purchased 1,250,000 Augmedix shares priced at $1.60 per share. The placement also included the purchase of 3,125,195 prefunded warrants, also priced at $1.60 each. Following the fresh investment, Redmile holds 44.7% of Augmedix's outstanding stock.
Tredegar $(TG)$
Gamco Investors $(GBL)$ increased its position in the maker of aluminum and plastics products to 4,643,343 shares. A combination of buys and sales from March 22 through April 20 added a net 343,312 Tredegar shares at prices ranging from $8.56 to $9.33 each. Gamco now owns 13.7% of Tredegar's tradable stock.
Decreases in Holdings
SunOpta (STKL)
Engaged Capital reduced its interest in the maker of plant-based foods and beverages to 5,500,000 shares. Engaged Capital, without citing a reason, sold 1,059,095 SunOpta shares from March 2 through April 21 at prices ranging from $7.41 to $8.59 apiece. Following the sales, Engaged Capital holds a 4.8% interest in SunOpta, below the 5% threshold that would require the disclosure of any further SunOpta stock sales. SunOpta is scheduled to report first-quarter earnings on May 10. SunOpta shares are about flat so far this year, but over the past 12 months, the stock has surged 50%.
Tela Bio $(TELA)$
OrbiMed Advisors lowered its holding in the soft-tissue-focused biotech to 2,835,542 shares, including 30,725 underlying exercisable warrants. OrbiMed sold 192,000 Tela Bio shares from April 19 through April 21 at per share prices ranging from $9.30 through $9.43. OrbiMed now holds an 11.9% stake in the biotech. On April 18, Tela Bio offered 4,750,000 shares in a public offering priced at $9.50 each, with a 30-day option for underwriters to purchase an additional 712,500 shares at the same offering price. The offering closed on April 21. Tela Bio will report first-quarter results on May 11.
Email: editors@barrons.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 28, 2023 18:47 ET (22:47 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。